Butyrate for IBS and Bloating: What the Research Actually Shows (2026)
Share
By Brandon, founder of Ozzi · Published August 30, 2026 · Updated October 31, 2026
Bloating is one of those symptoms people stop mentioning because they've been told so many times it's normal.
What is butyrate, and why does the gut care about it?
Butyrate is a short-chain fatty acid, and the gut cares about it because it mostly stays put and feeds the colon lining instead of being shipped off to the rest of the body.
If you want the full picture of the category, we wrote a complete guide to short-chain fatty acids that covers how each one is made and what it does.
What causes bloating in the first place?
Bloating is a symptom, not a diagnosis, and it has more than one cause. A few of the common ones:
- Gas from fermentation. Bacteria fermenting carbohydrates produce gas as a byproduct.
- Visceral sensitivity. Two people can have identical amounts of gas and only one feels it.
- Bacterial distribution. When fermentation happens higher up in the small intestine than it should, the sensation tends to be worse.
What has the research actually studied?
Butyrate has been studied in people diagnosed with IBS who were under medical care, and that context does not transfer automatically to a healthy person with occasional bloating.
In a randomized, double-blind, placebo-controlled trial published in Scientific Reports in 2026, researchers gave microencapsulated sodium butyrate or placebo to 52 patients who had both type 2 diabetes and met Rome IV criteria for IBS. Over 12 weeks, the butyrate group showed significant reductions in abdominal pain, diarrhea, and bloating, with bloating reaching p < 0.001. The placebo group showed no significant change. This was a human trial in a specific patient population, and it was small.
A 2025 randomized, placebo-controlled trial in the Journal of Pediatric Gastroenterology and Nutrition tested calcium butyrate in 51 children aged 4 to 17 with IBS diagnosed by Rome IV criteria. Treatment success reached 73% in the butyrate group versus 3.8% on placebo. Stool analysis showed increases in short-chain fatty acid producing bacteria including Lachnospiraceae, and a decrease in Ruminococcus gnavus, a taxon often elevated in inflammatory gut conditions. Again: human, but pediatric patients under specialist care.
A third trial, published in the Journal of Clinical Medicine, randomized 120 adults with IBS to a combination of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides, or to placebo, for 12 weeks. By week four, 64.7% of the biotic group reported adequate relief versus 42.0% on placebo. Worth flagging honestly: the trial found no significant difference in overall symptom severity scores or quality of life, which is a more mixed result than the headline suggests. It also tested a combination product, so butyrate cannot be credited alone.
| Study | Population | Evidence type | Finding |
|---|---|---|---|
| Panufnik 2026 | 52 adults, T2D + IBS | Human RCT | Bloating, pain, diarrhea reduced |
| Cristofori 2025 | 51 children with IBS | Human RCT | 73% vs 3.8% treatment success |
| Gąsiorowska 2025 | 120 adults with IBS | Human RCT, combination | Relief improved, severity scores unchanged |
| Scharf 2025 | 17 IBS, 17 healthy | Human, colonic perfusion | Reduced induced permeability |
| Souders 2023 | Primary rat colonocytes | Rodent, in vitro | Protected cells against inflammatory stress |
We keep the species label on every row on purpose. If you want more of our reasoning on this, we covered it in butyrate benefits, hype, and downsides.
How might butyrate affect bloating specifically?
Three plausible routes, ranked by how much human evidence sits behind each.
Barrier function. One colonoscopy study showed butyrate reducing induced permeability in human IBS tissue. Barrier integrity and bloating are linked in the research literature, though the connection is indirect. We go deeper on this in our piece on how to support gut barrier function naturally.
Bacterial composition. The pediatric trial found butyrate supplementation shifted the microbiota toward short-chain fatty acid producers and away from taxa associated with inflammation. Different fermenters produce different amounts of gas, so a shift in composition could plausibly change how much gas gets made.
Inflammatory tone. In primary rat colonocytes, butyrate protected against TNF-alpha induced cytotoxicity and preserved mitochondrial membrane potential. That's rodent work in a dish, so treat it as mechanism rather than proof. Our butyrate and inflammation post walks through what that literature does and doesn't establish.
Can you just eat more fiber instead?
Eating more fiber gets you part of the way, because your bacteria make butyrate from fermentable fiber, so feeding them is the original route.
Jerusalem artichoke, asparagus, garlic and oats all feed butyrate-producing bacteria.
The catch is that fermentable fiber is also gas-forming. If bloating is your main complaint, ramping fiber quickly is a reliable way to make things worse for a few weeks before they get better.
We laid out the workarounds in how to increase butyrate naturally.
What forms of butyrate supplement exist?
| Form | How it's delivered | Practical tradeoff |
|---|---|---|
| Sodium butyrate | Salt form, often microencapsulated | Most studied form; strong odor if uncoated |
| Calcium butyrate | Salt form, capsule or sachet | Used in the pediatric IBS trial |
| Tributyrin | Triglyceride carrying three butyrate units | Lipid-based; softgel format |
| L-Lysine Butyrate | Butyrate bound to the amino acid lysine | Water-dispersible; no human RCTs published |
We use L-Lysine Butyrate in Ozzi because it disperses in cold water without the odor problem that makes uncoated butyrate close to undrinkable. Being straight with you: there are no published human randomized trials on L-Lysine Butyrate specifically. The trials above used sodium and calcium forms. If you want the side-by-side, see sodium butyrate vs tributyrin and tributyrin vs lysine butyrate.
And if you've ever opened a butyrate supplement and wondered what happened, our post on why butyrate smells the way it does explains the chemistry. Butyric acid is the compound responsible for the smell of rancid butter, so the odor is just the molecule being itself rather than a manufacturing problem.
Where does Ozzi fit, honestly?
Ozzi is a daily drink stick built around appetite support, and gut support is part of how it's formulated. Each stick includes 500mg of L-Lysine Butyrate.
What Ozzi is not: a treatment for IBS. If you have persistent bloating, changes in bowel habit, unexplained weight loss, blood in your stool, or symptoms that wake you at night, that's a conversation with a doctor, not a supplement decision. IBS is a diagnosis of exclusion and it deserves a real workup.
If cravings and food noise are the bigger issue for you, our posts on how to quiet food noise and gut health and GLP-1 are the better starting point. A note on butyrate and GLP-1 specifically: the proposed link runs through L-cell stimulation and comes from cell and rodent work. No human study has shown butyrate raising GLP-1, and we'd rather say that plainly than let the mechanism drift into a claim.
Frequently asked questions
Does butyrate help with bloating?
Human trials in patients with IBS have reported reduced bloating with butyrate supplementation, including one 2026 trial where bloating improvement reached p < 0.001. Those trials were small and studied diagnosed patients under medical care.
Can butyrate make bloating worse?
Butyrate itself is not a fermentable substrate, so it doesn't produce gas the way fiber does. Prebiotic fibers packaged alongside it can cause temporary gas while your microbiome adjusts.
Is butyrate safe to take daily?
The trials above reported butyrate was safe and well tolerated over 8 to 12 weeks. Long-term data is limited. Check with your doctor if you're pregnant, nursing, on medication, or managing a diagnosed GI condition.
Butyrate and fiber, in one glass of water
Ozzi Crave Crusher gives you 500mg of L-Lysine Butyrate, alongside 8g of allulose for the sweet-craving side. 14-Day Ozzi Challenge: Take it for 14 straight days. If your cravings and food noise aren't quieter, we'll refund your first bag.
About the author. Brandon is the founder of Ozzi. He reads the primary literature before it goes into a product or a blog post, labels every mechanism claim by species, and would rather publish a smaller claim that holds up than a bigger one that doesn't. Ozzi's formula is built around allulose and L-Lysine Butyrate.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is educational and is not medical advice. Talk to a healthcare provider about persistent digestive symptoms.
References
- Panufnik P, et al. Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial. Scientific Reports. 2026. Human RCT. https://doi.org/10.1038/s41598-026-47309-9
- Cristofori F, et al. Calcium butyrate efficacy in pediatric irritable bowel syndrome: randomized placebo-controlled multiomics-based clinical trial. Journal of Pediatric Gastroenterology and Nutrition. 2025;81(3):551-561. Human RCT. https://doi.org/10.1002/jpn3.70154
- Gąsiorowska A, et al. Efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short chain fructooligosaccharides in patients with irritable bowel syndrome. Journal of Clinical Medicine. 2025;14(1):6. Human RCT. https://doi.org/10.3390/jcm14010006
- Scharf MW, et al. Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model. Gut Microbes. 2025;17(1):2545414. Human clinical trial. https://doi.org/10.1080/19490976.2025.2545414
- Souders CL, et al. Interaction between butyrate and tumor necrosis factor α in primary rat colonocytes. Biomolecules. 2023;13(2):258. Rodent, in vitro. https://doi.org/10.3390/biom13020258
- Liu Y, et al. Anti-inflammatory and barrier-protective effects of galacto-oligosaccharides and Limosilactobacillus reuteri M94: an in vitro microbiota-based assay. Food Research International. 2026;229:118487. In vitro. https://doi.org/10.1016/j.foodres.2026.118487
- Visuthranukul C, et al. Enhancing gut microbiota and microbial function with inulin supplementation in children with obesity. International Journal of Obesity. 2024;48(12):1696-1704. Human RCT. https://doi.org/10.1038/s41366-024-01590-8
